Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)
Open Posted
- Opportunity number
- PAR-24-311
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications due
- Award size
- Up to $500,000
Opportunity facts
- Assistance listings
-
- 93.395 Cancer Treatment Research
- 93.394 Cancer Detection and Diagnosis Research
- 93.396 Cancer Biology Research
- Funding instrument
- Grant
- Categories
-
- Education
- Health
- Eligible applicants
-
- City/Township Governments
- Non-501(c)(3) Nonprofits
- Other
- County Governments
- State Governments
- Public or Indian Housing Auth.
- Higher Education Inst. (Private)
- For Profit Organizations
- Tribal Organizations (Not Federally Recognized)
- Special District Governments
- Tribal Governments (Federally Recognized)
- 501(c)(3) Nonprofits
- Independent School Districts
- Small Businesses
- Higher Education Inst. (Public)
- Points of contact
-
- NIH OER Webmaster grantsinfo@nih.gov
- Full announcement
Opportunity details come from Grants.gov. Updated .
About this opportunity
The National Institutes of Health seeks R01 grant applications for molecular imaging research investigating inflammation in cancer, with applications due January 7, 2028. Clinical trials are explicitly not allowed under this funding mechanism.
Eligible applicants include higher education institutions (public and private), 501(c)(3) and non-501(c)(3) nonprofits, for-profit organizations, small businesses, city and county governments, state governments, tribal governments (federally recognized and not federally recognized), special district governments, independent school districts, and public or Indian housing authorities. Additionally eligible are Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions, Hispanic-serving Institutions, Historically Black Colleges and Universities, Tribally Controlled Colleges and Universities, faith-based or community-based organizations, eligible federal agencies, regional organizations, and U.S. territories or possessions. Non-domestic entities and non-domestic components of U.S. organizations are not eligible.
The program emphasizes development and use of current and emerging molecular imaging methods to interrogate cancer inflammation through in vivo approaches at the molecular and cellular level. Applications must demonstrate strong cross-field collaboration between cancer basic science researchers and imaging scientists. The initiative targets integrated imaging approaches that advance understanding of dynamic cancer-inflammation interactions and molecular changes in response to treatment, moving beyond the current reliance on in vitro and ex vivo methodologies.
Evaluation criteria assess scientific merit and significance of objectives, technical adequacy of experimental design, investigator competency, adequacy of facilities and resources, budget necessity, and relevance to program objectives.
The opportunity falls under three parent grant programs: Cancer Detection and Diagnosis Research (CFDA 93.394), Cancer Treatment Research (CFDA 93.395), and Cancer Biology Research (CFDA 93.396), all administered by the National Cancer Institute within the National Institutes of Health.
Synopsis
The purpose of this Notice of Funding Opportunity (NOFO) is to invite research grant applications (R01) for the development and use of current and emerging molecular imaging methods to gain fundamental insights into cancer inflammation in vivo. The motivation for this initiative is that much of current imaging research into the role of inflammation in cancer is largely based on in vitro and ex vivo methods with limited utilization of imaging approaches that could lead to significant new insights relevant to dynamic cancer and inflammation interactions. Utilization of molecular imaging probes in pre-clinical and clinical investigations for precise temporal resolution at the molecular and cellular level are valuable approaches for identification and characterization of in vivo inflammatory cellular physiology in cancers and of molecular changes in response to treatment. This FOA encourages applications that focus on developing integrated imaging approaches to interrogate the role of inflammation in cancer through strong cross-field collaboration between cancer basic science researchers and imaging scientists. These collaborations are expected to advance science and understanding of cancer inflammation interactions.
Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Files
| File | Type | Posted |
|---|---|---|
| PAR-24-311-Full-Announcement.html | HTML file | |
| PKG00288514.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity